SonoProbe®

High Intensity Contact Ultrasound Interstitial Medical Device

A new vision of surgery

“Surgery is undergoing rapid changes. Vascular diseases are now treated using endovascular techniques and extravascular pathologies are now treated using endoscopic and robotic techniques. This represents a significant change for the surgeon, who has the desire to minimize the aggressiveness of his actions. However, in the near future, these endoscopic and robotic techniques should give way to pure percutaneous techniques. Soon surgery will no longer be “open, sleep, pain and hospitalization,” but rather “diagnose, phenotype, coagulate, resect” and this will be done safely because all procedures will be performed under continuous image monitoring. This is the surgery of tomorrow. This change may seem impossible. Yet it is possible.” Pr Carpentier

This is the goal of the research performed by CarThera: develop a totally new medical technology that can be performed in a single outpatient procedure, under local anesthesia and using real-time MRI monitoring.

Between 2006 and 2009, Pr. Alexandre Carpentier, in collaboration with an American team, performed two clinical trials using a probe that emits laser energy to destroy brain tumors under real-time MRI control (A. Carpentier et al., Journal of Neurosurgery 2008; A. Carpentier et al., Lasers in Surgery and Medicine, 2011; A. Carpentier et al., Lasers in Surgery and Medicine, 2012). 

le monde couverture paint2

This first human trial allowed CarThera® to highlight the benefits of the use of MRI as an interventional tool and significantly increased patient survival (+12.8 months). But, several limitations were also noted: it was difficult to use the laser probe for treating complex tumor shapes; histological diagnosis during the procedure was not possible; and, it was not possible to extract necrotic tissue after the procedure, which created an undesirable mass effect after treatments.

 

 

 

sonde3 

 

The SonoProbe

At CarThera, we wanted to solve those three issues by developing a new probe that contains two major innovations:

(i) changing the energy source for inducing heating of tissue from a laser to ultrasound to allow for a better adaptation of the thermal treatment to the tumor shape without having to move the probe.

(ii) adding a central canal to the device to allow the surgeon to perform biopsies at the beginning of the treatment and to perform tissue removal at the end of the treatment to decrease the mass effect.

This is how the SonoProbe program was born.

 

  • unnamed-2
    unnamed-3

     
  • News CarThera

    25.06.2019
    June 2019: CarThera appoints Pascal E. R. Girin as chairman of board of directors

    Pascal Girin brings wealth of experience in medical device and life sciences industries to support CarThera’s future growth. Girin has decades of business expertise in the life sciences and medical devices markets, most recently as CEO of Balt, a leader in the treatment of neurovascular diseases. Prior to this, he held numerous C-level positions at leading medical companies, including Wright Medical, Keystone Dental (a Warburg Pincus company), EV3, Baxter and Ohmeda, among others. As chairman of CarThera’s board of directors, he will bring invaluable insight to the company’s business strategy and future development.

    25.06.2019
    March 19: CarThera publishes complete results of Phase I/IIa clinical trial using its SonoCloud-1 ultrasound implant

    Final results of the phase I/IIa clinical trial (NCT02253212) on the ultrasound-induced blood-brain barrier (BBB) opening improving the efficiency of carboplatin chemotherapy for recurrent glioblastoma patients were published in AACR’s Clinical Cancer Research journal of the . Study results show a good safety profile and encouraging efficacy. These results are based on 65 sonication sessions with escalating ultrasound pressure levels. GBM patients treated with optimal pressure levels and MRI-detected disrupted BBB (11 patients) showed a median progression-free survival (PFS) of 4.11 months and a median overall survival (OS) of 12.94 months. This compares to 2.73 months and 8.64 months respectively, for GBM patients without BBB disruption (8 patients).

    13.12.2018
    CarThera closes €9M ($10.3M) Series B funding round

    €9M ($10.3M) was raised with three institutional investors, Panakès Partners, Sham Innovation Santé (advised by Turenne Capital) and Supernova Invest via its fund Supernova 2, as well as Group Arnault and historical investors. The proceeds will be used to further advance the SonoCloud technology and develop the clinical pipeline of the company. A multi-center study has already been launched in France and in the US to evaluate the SonoCloud-9 device, a new generation of implant with nine ultrasound emitters, in patients with recurrent glioblastoma. The company also has an on-going clinical study with the SonoCloud-1 device in patients with Alzheimer’s disease and one planned for patients with brain metastases.